Vernalis receives 1.5m dollar payment through Genentech collaboration
AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group.
AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group.
The collaboration, which commenced in January 2012, aims to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.
Ian Garland, Chief Executive Officer of Vernalis, commented: "We are delighted to have achieved this success milestone under our collaboration with Genentech which further endorses the quality of our research group's work."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Vernalis' share price was up 1.59% to 24p at 11:38 on Monday.
Vernalis develops and commercialises low-risk late stage products for unmet medical need.
MF
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
New Chase bonus deal takes savings rate to 4.75% – is it worth it?
Chase’s latest savings deal propels it into first place in the best-buy tables, but there are some pitfalls to look out for
By Katie Williams Published
-
Review: Trasierra – a yoga retreat in the Spanish hills
Flora Connell joins a yoga retreat at Trasierra, in the Sierra Morena mountains north of Seville
By Flora Connell Published